Introduction
Breast cancer is the most frequent cancer in women worldwide, with the highest incidence in North America and Western Europe and the lowest levels in China and Japan (1) . In the UK 24 000 new cases of breast cancer are diagnosed each year and women have a lifetime risk of 1 in 12 of developing the disease (2) . Worldwide, 910 000 new cases are estimated to occur each year (3) .
Despite its common occurrence, the aetiology of breast cancer remains obscure. Known risk factors, such as higher than average lifetime exposure to endogenous oestrogens (resulting, for example, from having an early menarche and a late menopause) and family history of the disease (including inherited mutations in the BRCA1 and BRCA2 genes) account for only~30% of cases (4) .
In migrants moving from low to high risk countries, for example from Japan to the USA, the incidence rises to that of the host country in the second and third generations (1) . This suggests that dietary and/or environmental factors may play a role in the initiation of breast cancer.
Humans are exposed to a wide range of carcinogens in their environment (5) . Among these are the heterocyclic amines (HAs*) ('food mutagens') which are formed as pyrolysis products when, for example, meat is cooked at high temperatures. Around twenty HAs have been isolated and identified including 2-amino-3-methylimidazo [4,5- f]quinoline (IQ), 2-amino-3,4-dimethylimidazo [4,5- f]quinoline (MeIQ) and 2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (PhIP) (6) (7) (8) . Several have been shown to be mammary carcinogens in rodents (9, 10) and IQ has been shown to be a hepatocarcinogen in non-human primates (11) .
HAs are thought to induce tumours in the mammary gland after metabolic activation to reactive derivatives that form DNA adducts (10) . A variety of mechanisms for the metabolic activation of HAs have been proposed (10, (12) (13) (14) . One possible mechanism is a two-stage process with Phase I carried out by cytochrome P450 (CYP), CYP1A2 in the liver (15, 16) or CYP1A1 and CYP1B1 in the mammary gland (17) , to form N-hydroxy-HAs (N-OH-HAs), followed by a Phase II esterification reaction in which O-acetylation, catalysed by Nacetyltransferase (NAT), metabolically activates the N-OH-HA to N-acetoxy-HA. This then reacts with DNA to form HA-DNA adducts. Ghoshal et al. (10) have shown that, in the rat, CYP levels are extremely low in the mammary gland. This has led to the suggestion that the initial N-hydroxylation occurs in the liver, where the CYP levels are 500-fold higher (18) , and that the N-OH-HA may then be transported via the bloodstream to the mammary gland where an esterification reaction may occur. The NAT1 and NAT2 enzymes are polymorphic and acetylator status is dependent on NAT genotype (19) . The presence of any two germline copies of several variant alleles of NAT2 produces a slow acetylator phenotype (20) .
In this preliminary study we have investigated the metabolic activation of three heterocyclic amines (IQ, PhIP and MeIQ) and the N-OH-derivatives of two of them to DNA reactive species in primary cultures of human mammary epithelial cells (HMECs) from different individuals. We have also investigated the influence of NAT2 genotype on DNA adduct levels.
Materials and methods
Carcinogens IQ, MeIQ and PhIP were obtained from Toronto Research Chemicals (Ontario, Canada). N-hydroxy-2-amino-3-methylimidazo [4,5-f] quinoline (N-OH-IQ) and N-hydroxy-2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine (N-OHPhIP) were a gift from Dr Elizabeth Snyderwine, National Cancer Institute, Bethesda, MD.
Cell culture and carcinogen treatment
HMECs were prepared as organoids (clusters of luminal and myo-epithelial cells) by digestion of human mammary tissue removed at reduction mammoplasty (21, 22) . Briefly, 200-400 g of breast tissue were minced and digested using progressive collagenase digestion (type 1, Sigma), followed by sedimentation and sequential filtration through 140 µm and then 53 µm nylon mesh. The resulting organoids were seeded into 175 cm 2 flasks containing 50 ml RPMI 1640 medium with 10% fetal calf serum (FCS), supplemented with 2 mM L-glutamine, 100 µg/ml penicillin-streptomycin, 5 µg/ml hydrocortisone, 5 µg/ml insulin and 5 µg/ml cholera toxin. The flasks were gassed with 5% CO 2 in air and incubated at 37°C for 48 h to allow organoid attachment. The medium was changed and the culture maintained for a further 48 h. The epithelial cells were disaggregated using 0.25% trypsin-EDTA solution (Sigma) to form a single cell suspension (~1ϫ10 6 cells/ml, Ͼ90% viable by trypan blue exclusion) in RPMI 1640 and 10% FCS. Aliquots (2 ml) were treated either with HAs (IQ, MeIQ or PhIP) or with N-OH-HAs (N-OHPhIP or N-OH-IQ). A control suspension was treated with the solvent dimethyl sulphoxide (DMSO) alone. The suspensions were incubated at 37°C on a rotary shaker for 22 h before harvesting by centrifugation (200 g for 10 min) and storage at -85°C.
DNA isolation and 32 P-postlabelling assay
Cell pellets were thawed and resuspended in 10 mM EDTA/50 mM Tris pH 7.4. DNA was isolated according to the method of Gupta (23) and 32 Ppostlabelling analysis was carried out using the ATP-deficient method of Randerath (24) as described by Hall et al. (25) . DNA adducts were resolved on polyethyleneimine (PEI)-cellulose TLC plates using the following solvent system: D1, 1.0 M sodium phosphate, pH 6.0; D2, 2.3 M lithium formate, 5.5 M urea pH 3.5; D3, 0.8 M lithium chloride, 0.5 M Tris-HCl, 8.5 M urea pH 8.0; D4 1.7 M sodium phosphate pH 5.0. DNA adducts were detected and quantitated using an electronic two-dimensional scanner (Instant Imager, Canberra Packard, Pangbourne, Berkshire, UK). The level of DNA adducts was determined by relating levels of radioactivity in adducts to the specific activity of the [γ-32 P]ATP and expressed as relative adduct labelling (RAL adducts per 10 8 nucleotides) (26) .
NAT2 PCR-RFLP genotyping
The NAT2 genotype was determined using the polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method of Bell et al. and 72°C for 90 s. This was followed by a final extension at 72°C for 5 min. Aliquots (20 µl) of the PCR products were removed and digested with restriction enzymes (New England Biolabs, Hertfordshire, UK): Kpn1 for the NAT2*5A (M1) allele, Taq1 for the NAT2*6A (M2) allele, BamH1 for the NAT2*7A (M3) allele and Msp1/Alu1 for the NAT2*14A (M4) allele. The Kpn1, BamHI and Msp1/Alu1 digests were performed at 37°C and the Taq1 digest at 65°C for 2-3 h. Agarose gel electrophoresis (7 V/cm) was carried out on the digests in TBE (89 mM Tris base, 89 mM borate, 2 mM EDTA) buffer containing 0.25 mg/ml ethidium bromide. The gels were photographed under UV light. Each NAT2 genotype was designated as a slow acetylator if any two variant alleles (M1-M4) were present, and as a fast acetylator if one or both alleles were wild-type (NAT2*4) (20) . The wild-type allele is cut by each of the restriction enzymes whereas the variant allele remains uncut due to a loss of the corresponding restriction site.
Statistical analysis
Statistical analysis was performed using a Mann-Whitney non-parametric U-test to determine if there were significant differences between levels of adducts observed in cells from designated slow and fast acetylators.
Linear regression analysis was used to determine if the extent of metabolic activation of different heterocyclic amines varies in HMECs obtained from the same donor.
Results

DNA adduct formation by HAs and N-OH-HAs
When primary HMEC samples were treated with the HAs; IQ, MeIQ or PhIP or with the N-OH derivatives; N-OH-PhIP or N-OH-IQ, DNA adducts that were detectable by 32 Ppostlabelling were formed (see Figure 1 ). IQ and MeIQ both produced a similar pattern of adduct spots, with several major partially resolved adduct spots distinguishable in all samples. Incubation with PhIP also gave rise to several major partially resolved adduct spots; these adduct spots were less intense than those formed by IQ or MeIQ. The N-OH derivatives gave a similar adduct pattern to those formed by their respective parent compounds PhIP and IQ. Adduct patterns formed by N-OH-PhIP were more intense than those formed by PhIP with four distinct spots observed in all samples. The N-OH-IQ adducts formed at least three major adduct spots with a more intense pattern than IQ. Dose response DNA adducts formed in cultures of primary HMECs treated with MeIQ or IQ (125 µM-1000 µM), PhIP (250 µM- (Table I ). The total level of adducts detected in the DNA from individual donors ranged, for IQ, from 0.64-63.1 (mean 7.80) adducts per 10 8 nucleotides and for MeIQ, from 1.99-17.8 (mean 6.63). PhIP gave rise to total adduct levels ranging from 0.13-4.0 (mean 0.96) adducts per 10 8 nucleotides.
When HMECs were treated with 20 µM of N-OH-PhIP or N-OH-IQ, higher adduct levels were detected than were found following incubation with the parent compounds at a 25-fold higher concentration (500 µM). Total DNA adducts for N-OHPhIP ranged from 6.32-497 (mean 176) and for N-OH-IQ from 0.92-30.6 (mean 9.24) adducts per 10 8 nucleotides.
Comparison of DNA adduct levels formed by different heterocyclic amines in cells from the same individuals
Aliquots of primary HMEC suspensions (2 ml) from each donor were treated with IQ, MeIQ, PhIP, N-OH-PhIP or N-OH-875 IQ and the DNA adduct levels compared to determine if any correlation existed between the extent of metabolic activation of different substrates in cells from the same individual (see Figure 3 ). Linear regression analysis showed a significant correlation between DNA adduct levels formed by IQ and MeIQ (r 2 ϭ 0.701, P ϭ 0.0003) whereas there was no significant correlation between IQ and PhIP (r 2 ϭ 0.000028, P ϭ 0.985) or between MeIQ and PhIP (r 2 ϭ 0.0063, P ϭ 0.816). When IQ and its metabolic intermediate N-OH-IQ were compared, a significant correlation was observed (r 2 ϭ 0.738, P ϭ 0.0062), with individuals showing higher IQ adduct levels also showing higher N-OH-IQ adduct levels at a 25-fold lower concentration. In contrast there was no significant correlation between adduct levels in PhIP and N-OH-PhIP treated cells from the same individual (r 2 ϭ 0.11, P ϭ 0.38). N-OH-PhIP at a 25-fold lower concentration than that of PhIP produced up to 400-fold higher adduct levels than its parent compound (see Figure 3) . When N-OH-IQ and N-OH-PhIP were compared at the same concentration a significant correlation between adduct levels was found (r 2 ϭ 0.753, P ϭ 0.0113). NAT2 and adduct formation The NAT2 genotype was determined for each of the individuals and compared to the DNA adduct levels to see whether acetylator status correlated with HA-DNA-adduct levels ( Figure 4 ). For each of the five compounds (IQ, PhIP, MeIQ, N-OH-IQ and N-OH-PhIP) a higher mean level of DNA adducts was observed in individuals who were NAT2 fast acetylators. However, the difference between the total levels of DNA adducts observed in cells from individuals designated fast or slow acetylators was not found to be statistically significant (see Table II ).
Discussion
In this study we have shown that both the parent HAs and their N-OH-HA derivatives are activated in primary cultures of HMECs to produce a pattern of DNA adduct spots similar to those found, following treatment, in rodent mammary gland (9,10) and in extrahepatic tissues of monkeys (27, 28) . HAs have also been shown to cause tumours in rat mammary glands (29) .
The N-OH derivatives of IQ and PhIP produce adduct patterns similar to those seen following treatment with their respective parent amines. The N-OH metabolites produced significantly higher adduct levels at a 25-fold lower concentration in both cases. In all the individuals whose cells have been examined so far, the levels of adducts formed in primary HMECs by N-OH-PhIP were higher than those formed by N-OH-IQ and this is consistent with the data on adduct formation reported by Fan et al. (30) using HMECs that had undergone 11-13 passages in culture. When the metabolic activation of IQ, MeIQ and PhIP was compared, there was a significant correlation between the levels of DNA adducts formed by IQ and MeIQ but no correlation between levels of PhIP adducts and IQ or MeIQ adducts. This suggests that the metabolic activation of PhIP in mammary epithelial cells is different in some way from that of IQ and MeIQ and it could, for example, conceivably indicate that sulphation is involved in the activation of N-OH-PhIP (13) or that the acetoxy ester is selectively detoxified (16) . The adduct levels detected for PhIP were much lower than for the other two HAs, suggesting that PhIP-DNA adducts are not formed to the same extent as those of MeIQ and IQ. Alternatively PhIP adducts may be 32 P-postlabelled less efficiently than adducts formed by other HAs. The greater amounts of adduct formation detected in HMECs treated with the N-hydroxylated compounds indicates that the N-hydroxylation step (Phase I) may be the rate-limiting step in these cells and that the levels of CYP isoforms in HMECs are low. Thus the Phase II O-acetylation step is thought to be the significant step in HA metabolic activation that occurs in the breast. Ghoshal et al. proposed that, in rodents, the Phase I reaction occurs predominantly in the liver via N-hydroxylation, to yield N-OH-PhIP, which is carried in the blood stream to the mammary gland, where Phase II activation to DNA reactive species may take place (10). Our results are in broad agreement with this proposal.
An alternative hypothesis for the Phase I reaction has been proposed by Josephy (12) who suggested that, since CYP levels are low in the breast, peroxidases present in neutrophils in blood and breast milk may catalyse sequential one-electron oxidation of aromatic amines, to generate reactive electrophiles which can bind to DNA. These peroxidases may catalyse metabolic activation of aromatic amines, including for example, 876 PhIP, within the breast ducts, thus exposing the epithelial cells to activated forms of these carcinogens.
However, some Phase I metabolic activation must occur in vitro in primary HMECs for DNA adducts to be formed from the HAs, as presented in this paper and in our previous studies (31, 32) . This is in contrast to the lack of adducts detected when Fan et al. (30) incubated passage 11 HMECs with 50 µM IQ or PhIP for 24 h. However in the present study, we detected IQ-DNA adducts and PhIP-DNA adducts after 22 h incubation at 37°C, at a concentration of 125 µM and 250 µM respectively, in primary cultures of HMECs (Figure 2 ). This finding suggests that cells passaged in culture lose their CYP enzyme activity (33) and thus their ability to N-hydroxylate HAs. The primary HMECs used here, which have been in culture for only 4 days, probably still possess low levels of CYP and may therefore be closer to the in vivo situation. The most abundant CYP in human breast are CYP1B1 and CYP1A1 (34, 35) and these conceivably carry out the limited Phase I activation of HAs detected in the present study.
Several studies have demonstrated a link between NAT activity and DNA adduct formation (36, 37) . Messenger RNA transcripts for NAT1 and NAT2 have been detected in mammary tissue (36) and our own preliminary studies have confirmed this finding (unpublished data). These studies support the role of NATs in DNA adduct formation by HAs in HMECs. Experiments are in progress to determine the level of expression of these genes in isolated cells. Nerurkar et al. (37) studied the effects of Ah (Aryl hydrocarbon) locus and acetylator polymorphisms in mice on IQ-DNA adduct levels and showed that mice with both Ah non-responsive and rapid acetylator genotypes had a three-fold increase in adduct levels in the colon. In humans, NAT2 status and smoking have been shown to influence the occurrence of breast cancer, with smokers who were NAT2 slow acetylators more prone to developing breast cancer than non smokers (38) . Also a possible link between NAT2 genotype and levels of pre-existing adducts in human breast tissue has been demonstrated (W.Pfau, E.M.Stone, U.Brockstedt, P.L.Carmichael, H.Marquardt and D.H.Phillips, manuscript in preparation) showing that there are significantly higher levels of DNA adducts in slow NAT2 acetylators compared with those having the rapid NAT2 genotype. It is also thought that slow NAT2 (detoxification) and rapid NAT1 (activation) increase the risk of humans developing cancers such as bladder cancer (39) . Other Phase II enzymes such as sulfotransferases may also catalyse esterification of N-OH-HAs (13, 14) . Davis et al. (13) examined the in vitro phase II activation of N-OH-PhIP and N-OH-IQ by cytosolic acetyltransferases, sulfotransferases, aminoacyl-tRNA synthetase and phosphatase in liver, kidney, heart, colon and heart of rat and monkey and showed that all four enzymes may be involved in the activation of N-OHHAs, depending on the particular substrate used. N-OH-IQ was found to be activated by most of the enzymes apart from the sulfotransferases; in contrast N-OH-PhIP was also activated by sulfotransferases in the liver of monkeys (13) . Therefore, activation of N-OH-PhIP may thus proceed by a different pathway to that of N-OH-IQ. Other evidence that PhIP is activated differently from other HAs has been obtained from bacterial mutagenicity studies. Wild et al. have shown that strains of Salmonella typhimurium expressing human NAT2 activated IQ and MeIQ but not PhIP (40) .
There are still differing opinions on whether NAT2 metabolises N-OH-HAs by O-acetylation, N-acetylation or both (41) but the general view is that NAT2 O-acetylates N-OHHAs (40, 42) . Although we observed a slight increase in adduct levels in cells with a rapid NAT2 acetylator genotype, the difference was not significant in this size of study. A larger study will be required to determine whether this observation can be reproduced and achieve statistical significance. Several studies have demonstrated that pre-existing DNA adducts are present in human breast tissue (43) (44) (45) . Li et al. reported higher adduct levels in tumour-adjacent breast tissue from cancer patients compared with the levels observed in reduction mammoplasty (control) patients (43) . In another study DNA adducts were detected in three out of ten untreated reduction mammoplasty samples (44) . However the identity of these adducts remains to be determined.
In summary, this pilot study demonstrates large interindividual variations in the metabolic activation of HAs by primary cultures of HMECs. Since we observed a similar pattern of adduct spots from two HAs and from their related N-OH-HAs this shows that activation of HAs proceeds via N-OH-HAs in the mammary gland. A greater extent of activation of N-OHHAs, even at a 25-fold lower concentration than was used with the corresponding HAs, suggests that the mammary epithelial cells play a greater role in Phase II metabolic activation of these compounds than Phase I, although there is conflicting evidence in the literature concerning the nature of the esterified forms of HAs and N-OH-HAs that are precursors of DNA adduct formation.
